Swiss clinical practice guidelines for skin cancer in organ transplant recipients

Patients with a solid organ transplant have increased in numbers and in individual survival in Switzerland over the last decades. As a consequence of long-term immunosuppression, skin cancer in solid organ recipients (SOTRs) has been recognized as an important problem. Screening and education of pot...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Swiss medical weekly 2009-07, Vol.139 (29-30), p.407-415
Hauptverfasser: Hofbauer, G F, Anliker, M, Arnold, A, Binet, I, Hunger, R, Kempf, W, Laffitte, E, Lapointe, A C, Pascual, M, Pelloni, F, Serra, A
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 415
container_issue 29-30
container_start_page 407
container_title Swiss medical weekly
container_volume 139
creator Hofbauer, G F
Anliker, M
Arnold, A
Binet, I
Hunger, R
Kempf, W
Laffitte, E
Lapointe, A C
Pascual, M
Pelloni, F
Serra, A
description Patients with a solid organ transplant have increased in numbers and in individual survival in Switzerland over the last decades. As a consequence of long-term immunosuppression, skin cancer in solid organ recipients (SOTRs) has been recognized as an important problem. Screening and education of potential SOTRs about prevention of sun damage and early recognition of skin cancer are important before transplantation. Once transplanted, SOTRs should be seen by a dermatologist yearly for repeat education as well as early diagnosis, prevention and treatment of skin cancer. Squamous cell carcinoma of the skin (SCC) is the most frequent cancer in the setting of long-term immunosuppression. Sun protection by behaviour, clothing and daily sun screen application is the most effective prevention. Cumulative sun damage results in field cancerisation with numerous in-situ SCC such as actinic keratosis and Bowen's disease which should be treated proactively. Invasive SCC is cured by complete surgical excision. Early removal is the best precaution against potential metastases of SCC. Reduction of immunosuppression and switch to mTOR inhibitors and potentially, mycophenolate, may reduce the incidence of further SCC. Chemoprevention with the retinoid acitretin reduces the recurrence rate of SCC. The dermatological follow-up of SOTRs should be integrated into the comprehensive post-transplant care.
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_67576891</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67576891</sourcerecordid><originalsourceid>FETCH-LOGICAL-p209t-7b9272dc0ba310a141437a61ce4e8edbc473b5e2b619f0e1c6d5550e8c31f1593</originalsourceid><addsrcrecordid>eNo1kE1LxDAYhHNQ3HX1L0hO3gpJ03z0KItfsCCinkvy9u0S7aYxSRH_vQV3TzMMD8MwZ2TNm7qptFFsRS5z_mSsNorLC7LirTLMCLYmr28_PmcKow8e7EhjslA8IN3PvsclxUyHKdH85QMFGwATXdyU9jbQkmzIcbSh0ITgo8dQ8hU5H-yY8fqoG_LxcP--fap2L4_P27tdFWvWlkq7ttZ1D8xZwZnlDW-EtooDNmiwd9Bo4STWTvF2YMhB9VJKhgYEH7hsxYbc_vfGNH3PmEt38BlwXObgNOdOaamVafkC3hzB2R2w72LyB5t-u9MJ4g-tylhp</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67576891</pqid></control><display><type>article</type><title>Swiss clinical practice guidelines for skin cancer in organ transplant recipients</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Alma/SFX Local Collection</source><creator>Hofbauer, G F ; Anliker, M ; Arnold, A ; Binet, I ; Hunger, R ; Kempf, W ; Laffitte, E ; Lapointe, A C ; Pascual, M ; Pelloni, F ; Serra, A</creator><creatorcontrib>Hofbauer, G F ; Anliker, M ; Arnold, A ; Binet, I ; Hunger, R ; Kempf, W ; Laffitte, E ; Lapointe, A C ; Pascual, M ; Pelloni, F ; Serra, A ; SGDV working group for organ transplant recipients</creatorcontrib><description>Patients with a solid organ transplant have increased in numbers and in individual survival in Switzerland over the last decades. As a consequence of long-term immunosuppression, skin cancer in solid organ recipients (SOTRs) has been recognized as an important problem. Screening and education of potential SOTRs about prevention of sun damage and early recognition of skin cancer are important before transplantation. Once transplanted, SOTRs should be seen by a dermatologist yearly for repeat education as well as early diagnosis, prevention and treatment of skin cancer. Squamous cell carcinoma of the skin (SCC) is the most frequent cancer in the setting of long-term immunosuppression. Sun protection by behaviour, clothing and daily sun screen application is the most effective prevention. Cumulative sun damage results in field cancerisation with numerous in-situ SCC such as actinic keratosis and Bowen's disease which should be treated proactively. Invasive SCC is cured by complete surgical excision. Early removal is the best precaution against potential metastases of SCC. Reduction of immunosuppression and switch to mTOR inhibitors and potentially, mycophenolate, may reduce the incidence of further SCC. Chemoprevention with the retinoid acitretin reduces the recurrence rate of SCC. The dermatological follow-up of SOTRs should be integrated into the comprehensive post-transplant care.</description><identifier>ISSN: 1424-7860</identifier><identifier>PMID: 19680830</identifier><language>eng</language><publisher>Switzerland</publisher><subject>Acitretin - therapeutic use ; Anticarcinogenic Agents - therapeutic use ; Carcinoma, Squamous Cell - immunology ; Carcinoma, Squamous Cell - prevention &amp; control ; Humans ; Immunocompromised Host ; Organ Transplantation - adverse effects ; Skin Neoplasms - immunology ; Skin Neoplasms - prevention &amp; control ; Sunscreening Agents - therapeutic use</subject><ispartof>Swiss medical weekly, 2009-07, Vol.139 (29-30), p.407-415</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/19680830$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hofbauer, G F</creatorcontrib><creatorcontrib>Anliker, M</creatorcontrib><creatorcontrib>Arnold, A</creatorcontrib><creatorcontrib>Binet, I</creatorcontrib><creatorcontrib>Hunger, R</creatorcontrib><creatorcontrib>Kempf, W</creatorcontrib><creatorcontrib>Laffitte, E</creatorcontrib><creatorcontrib>Lapointe, A C</creatorcontrib><creatorcontrib>Pascual, M</creatorcontrib><creatorcontrib>Pelloni, F</creatorcontrib><creatorcontrib>Serra, A</creatorcontrib><creatorcontrib>SGDV working group for organ transplant recipients</creatorcontrib><title>Swiss clinical practice guidelines for skin cancer in organ transplant recipients</title><title>Swiss medical weekly</title><addtitle>Swiss Med Wkly</addtitle><description>Patients with a solid organ transplant have increased in numbers and in individual survival in Switzerland over the last decades. As a consequence of long-term immunosuppression, skin cancer in solid organ recipients (SOTRs) has been recognized as an important problem. Screening and education of potential SOTRs about prevention of sun damage and early recognition of skin cancer are important before transplantation. Once transplanted, SOTRs should be seen by a dermatologist yearly for repeat education as well as early diagnosis, prevention and treatment of skin cancer. Squamous cell carcinoma of the skin (SCC) is the most frequent cancer in the setting of long-term immunosuppression. Sun protection by behaviour, clothing and daily sun screen application is the most effective prevention. Cumulative sun damage results in field cancerisation with numerous in-situ SCC such as actinic keratosis and Bowen's disease which should be treated proactively. Invasive SCC is cured by complete surgical excision. Early removal is the best precaution against potential metastases of SCC. Reduction of immunosuppression and switch to mTOR inhibitors and potentially, mycophenolate, may reduce the incidence of further SCC. Chemoprevention with the retinoid acitretin reduces the recurrence rate of SCC. The dermatological follow-up of SOTRs should be integrated into the comprehensive post-transplant care.</description><subject>Acitretin - therapeutic use</subject><subject>Anticarcinogenic Agents - therapeutic use</subject><subject>Carcinoma, Squamous Cell - immunology</subject><subject>Carcinoma, Squamous Cell - prevention &amp; control</subject><subject>Humans</subject><subject>Immunocompromised Host</subject><subject>Organ Transplantation - adverse effects</subject><subject>Skin Neoplasms - immunology</subject><subject>Skin Neoplasms - prevention &amp; control</subject><subject>Sunscreening Agents - therapeutic use</subject><issn>1424-7860</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2009</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1kE1LxDAYhHNQ3HX1L0hO3gpJ03z0KItfsCCinkvy9u0S7aYxSRH_vQV3TzMMD8MwZ2TNm7qptFFsRS5z_mSsNorLC7LirTLMCLYmr28_PmcKow8e7EhjslA8IN3PvsclxUyHKdH85QMFGwATXdyU9jbQkmzIcbSh0ITgo8dQ8hU5H-yY8fqoG_LxcP--fap2L4_P27tdFWvWlkq7ttZ1D8xZwZnlDW-EtooDNmiwd9Bo4STWTvF2YMhB9VJKhgYEH7hsxYbc_vfGNH3PmEt38BlwXObgNOdOaamVafkC3hzB2R2w72LyB5t-u9MJ4g-tylhp</recordid><startdate>20090725</startdate><enddate>20090725</enddate><creator>Hofbauer, G F</creator><creator>Anliker, M</creator><creator>Arnold, A</creator><creator>Binet, I</creator><creator>Hunger, R</creator><creator>Kempf, W</creator><creator>Laffitte, E</creator><creator>Lapointe, A C</creator><creator>Pascual, M</creator><creator>Pelloni, F</creator><creator>Serra, A</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20090725</creationdate><title>Swiss clinical practice guidelines for skin cancer in organ transplant recipients</title><author>Hofbauer, G F ; Anliker, M ; Arnold, A ; Binet, I ; Hunger, R ; Kempf, W ; Laffitte, E ; Lapointe, A C ; Pascual, M ; Pelloni, F ; Serra, A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p209t-7b9272dc0ba310a141437a61ce4e8edbc473b5e2b619f0e1c6d5550e8c31f1593</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2009</creationdate><topic>Acitretin - therapeutic use</topic><topic>Anticarcinogenic Agents - therapeutic use</topic><topic>Carcinoma, Squamous Cell - immunology</topic><topic>Carcinoma, Squamous Cell - prevention &amp; control</topic><topic>Humans</topic><topic>Immunocompromised Host</topic><topic>Organ Transplantation - adverse effects</topic><topic>Skin Neoplasms - immunology</topic><topic>Skin Neoplasms - prevention &amp; control</topic><topic>Sunscreening Agents - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hofbauer, G F</creatorcontrib><creatorcontrib>Anliker, M</creatorcontrib><creatorcontrib>Arnold, A</creatorcontrib><creatorcontrib>Binet, I</creatorcontrib><creatorcontrib>Hunger, R</creatorcontrib><creatorcontrib>Kempf, W</creatorcontrib><creatorcontrib>Laffitte, E</creatorcontrib><creatorcontrib>Lapointe, A C</creatorcontrib><creatorcontrib>Pascual, M</creatorcontrib><creatorcontrib>Pelloni, F</creatorcontrib><creatorcontrib>Serra, A</creatorcontrib><creatorcontrib>SGDV working group for organ transplant recipients</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Swiss medical weekly</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hofbauer, G F</au><au>Anliker, M</au><au>Arnold, A</au><au>Binet, I</au><au>Hunger, R</au><au>Kempf, W</au><au>Laffitte, E</au><au>Lapointe, A C</au><au>Pascual, M</au><au>Pelloni, F</au><au>Serra, A</au><aucorp>SGDV working group for organ transplant recipients</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Swiss clinical practice guidelines for skin cancer in organ transplant recipients</atitle><jtitle>Swiss medical weekly</jtitle><addtitle>Swiss Med Wkly</addtitle><date>2009-07-25</date><risdate>2009</risdate><volume>139</volume><issue>29-30</issue><spage>407</spage><epage>415</epage><pages>407-415</pages><issn>1424-7860</issn><abstract>Patients with a solid organ transplant have increased in numbers and in individual survival in Switzerland over the last decades. As a consequence of long-term immunosuppression, skin cancer in solid organ recipients (SOTRs) has been recognized as an important problem. Screening and education of potential SOTRs about prevention of sun damage and early recognition of skin cancer are important before transplantation. Once transplanted, SOTRs should be seen by a dermatologist yearly for repeat education as well as early diagnosis, prevention and treatment of skin cancer. Squamous cell carcinoma of the skin (SCC) is the most frequent cancer in the setting of long-term immunosuppression. Sun protection by behaviour, clothing and daily sun screen application is the most effective prevention. Cumulative sun damage results in field cancerisation with numerous in-situ SCC such as actinic keratosis and Bowen's disease which should be treated proactively. Invasive SCC is cured by complete surgical excision. Early removal is the best precaution against potential metastases of SCC. Reduction of immunosuppression and switch to mTOR inhibitors and potentially, mycophenolate, may reduce the incidence of further SCC. Chemoprevention with the retinoid acitretin reduces the recurrence rate of SCC. The dermatological follow-up of SOTRs should be integrated into the comprehensive post-transplant care.</abstract><cop>Switzerland</cop><pmid>19680830</pmid><tpages>9</tpages></addata></record>
fulltext fulltext
identifier ISSN: 1424-7860
ispartof Swiss medical weekly, 2009-07, Vol.139 (29-30), p.407-415
issn 1424-7860
language eng
recordid cdi_proquest_miscellaneous_67576891
source MEDLINE; DOAJ Directory of Open Access Journals; Alma/SFX Local Collection
subjects Acitretin - therapeutic use
Anticarcinogenic Agents - therapeutic use
Carcinoma, Squamous Cell - immunology
Carcinoma, Squamous Cell - prevention & control
Humans
Immunocompromised Host
Organ Transplantation - adverse effects
Skin Neoplasms - immunology
Skin Neoplasms - prevention & control
Sunscreening Agents - therapeutic use
title Swiss clinical practice guidelines for skin cancer in organ transplant recipients
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T07%3A09%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Swiss%20clinical%20practice%20guidelines%20for%20skin%20cancer%20in%20organ%20transplant%20recipients&rft.jtitle=Swiss%20medical%20weekly&rft.au=Hofbauer,%20G%20F&rft.aucorp=SGDV%20working%20group%20for%20organ%20transplant%20recipients&rft.date=2009-07-25&rft.volume=139&rft.issue=29-30&rft.spage=407&rft.epage=415&rft.pages=407-415&rft.issn=1424-7860&rft_id=info:doi/&rft_dat=%3Cproquest_pubme%3E67576891%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67576891&rft_id=info:pmid/19680830&rfr_iscdi=true